Clinical Trial

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)

MOA: Fruquintinib is a highly selective and potent VEGFR inhibitor.

Key Eligibility Criteria:

• Subjects must have confirmed mCRC
• Subjects with genetic aberrations are allowed
• No MSI-H and BRAF V600
• Subjects must have received FOLFOX and BEV-based first line of therapy
• Subjects that received more than 1 treatment regimen for mCRC are excluded
• Subjects that have received neo/adjuvant therapy and were disease free for >6 months before recurrence are eligible
• Subjects who received neo/adjuvant FOLFOX and progressed within 6 months are excluded
• ECOG score ≤ 2